• Adults, age 18-88 years of age.
• English-speaking.
• Have undergone radical cystectomy for the treatment of bladder cancer at Mayo Clinic'c campus in Jacksonville, FL.
• Able and willing to consent to participate in phone interview.

• Individuals < 18 years if age or ≥ 89 years of age.
• Non-English speaking.
• Unable or unwilling to provide informed consent.
• Having undergone radical cystectomy for a reason other than bladder cancer.

Eligibility last updated 2/25/22. Questions regarding updates should be directed to the study team contact.

• Adult (≥ 18 years of age) traumatic brachial plexus injury (BPI) patients who underwent spinal accessory nerve or intercostal nerves transfer to musculocutaneous nerve or branch to biceps from Jan 1 2010 to Dec 31 2020.
• Once consented, they will be given an appointment to return to the Mayo Clinic Brachial Plexus clinic for a physical follow-up to undergo a standard post nerve reconstruction evaluation.  For patients who consented but are not able to travel to Mayo Clinic for a physical review, a virtual consult will be scheduled. 

• Patients less than 18 years old and those with brachial plexus palsy resulting from birth injury, compressive neuropathy, resection of tumors, cervical spine surgery, radiation therapy, inflammatory or auto-immune conditions will be excluded.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/11/23. Questions regarding updates should be directed to the study team contact.

• Age 18 or older.
• Diagnosis of keratoconus.
• Available baseline corneal topography and pachymetry.
• Amsler-Krumeich keratoconus classification of stage 1 or higher.

• No prior corneal transplantation or INTACTS.
• No prior use of hybrid, corneal or scleral gas permeable lenses.
• Presence of corneal scarring.

Eligibility last updated 9/17/21. Questions regarding updates should be directed to the study team contact.

Inclusoin Criteria: 

• Documentation of the participant’s informed consent to study procedures and for the use of PHI (HIPAA Authorization, if applicable):
  • NOTE: Informed consent processes and documentation must adhere to state laws/local requirements, including consent provided by the participant’s legally authorized representative (LAR), responsible next of kin, surrogate consent with assent, etc.
• Previously consented to participate in A3-45 screening.
• Has A3-45 screening plasma biomarker results required for determining eligibility to participate in the A3-45 trial.
• If an amyloid PET scan was conducted in A3-45, the scan was determined to be below the 20 centiloid cutpoint required for eligibility into the treatment arms of the A3 or A45 trial.
• As assessed by the site PI, participant is likely to be able to comply with the protocol, including completion of all required procedures for the duration of the study, and has adequate vision, hearing (hearing aid permitted), and literacy in English or Spanish sufficient for compliance with required testing procedures.

• Current treatment with an FDA approved medication for Alzheimer’s disease, including prior or current treatment with a prohibited medication as described in section 6.2.1.
• Enrollment in another investigational study, or intake of investigational drug, within 30 days prior to screening, or five halflives of the investigational drug, whichever is longer, unless it can be documented that the participant was in the placebo treatment arm.
• NOTE: Participants enrolled in other observational studies may be permitted with Medical Monitor review and approval.
• Screen failed from A3-45 due to not meeting basic inclusion criterion (i.e., age requirement; current diagnosis of AD dementia).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/4/23. Questions regarding updates should be directed to the study team contact.

• ≥ 75+ years
• Part of National Patient-Centered Clinical Research Network (PCORnet) and the Veterans Affairs (VA) system.
• Enrolled in the PREVENTABLE trial.

• < 75 years of age. 

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/25/23. Questions regarding updates should be directed to the study team contact.

• ≥ 18 years of age.
• Fall into one of the following categories: clinical geneticist, genetic counselor, scientist, investigator, physician working at, or are members of, professional organizations in the spaces of genetics and/or human reproduction.
• Willing and able to participate in study activities in either Spanish or English.

• Under 18 years of age.
• Unable or lack the capacity to provide consent; Individuals who are not clinicians or scientists working at, or are members of, professional organizations in the spaces of genetics and/or human reproduction.
• Does not speak English or Spanish.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/1/22. Questions regarding updates should be directed to the study team contact.